Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2014; 20(16): 4681-4691
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4681
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4681
Table 2 Response outcome
Response type | n = 46 |
End of treatment response | 13 (28.2) |
SVR | 11 (23.9) |
Dropped out SVR | 2 (4.3) |
Non-responder | 14 (30.4) |
Breakthrough | 18 (39.1) |
Delayed responders ended by breakthrough | 8 (17.4) |
Breakthrough ended at 48 wk as non-responders | 8 (17.4) |
Breakthrough ended at 72 wk by relapse | 2 (4.3) |
Relapse | 1 (2.17) |
-
Citation: Naghi SE, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM. Safety and efficacy of
Hansenula -derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol 2014; 20(16): 4681-4691 - URL: https://www.wjgnet.com/1007-9327/full/v20/i16/4681.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i16.4681